Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice

Vincent Braunersreuther; Fabrizio Montecucco; Graziano Pelli; Katia Galan; Amanda E. Proudfoot; Alexandre Belin; Nicolas Vuilleumier; Fabienne Burger; Sébastien Lenglet; Irene Caffa; Debora Soncini; Alessio Nencioni; Jean-Paul Vallée; François Mach

doi:10.1160/TH13-04-0297

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2013; 110(04): 807-825
DOI: 10.1160/TH13-04-0297

Cardiovascular Biology and Cell Signalling

Schattauer GmbH

Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice

Authors

Vincent Braunersreuther^*

¹Division of Cardiology, Foundation for Medical Researches, Faculty of Medicine, Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland
Fabrizio Montecucco^*

¹Division of Cardiology, Foundation for Medical Researches, Faculty of Medicine, Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland

²First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Graziano Pelli

¹Division of Cardiology, Foundation for Medical Researches, Faculty of Medicine, Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland
Katia Galan

¹Division of Cardiology, Foundation for Medical Researches, Faculty of Medicine, Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland
Amanda E. Proudfoot

³Merck Serono Geneva Research Centre, Geneva, Switzerland
Alexandre Belin

⁴Department of Radiology – CIBM, Geneva, University Hospital, Geneva, Switzerland
Nicolas Vuilleumier

⁵Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Switzerland

⁶Department of Human Protein Science, Geneva Faculty of Medicine, Geneva, Switzerland
Fabienne Burger

¹Division of Cardiology, Foundation for Medical Researches, Faculty of Medicine, Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland
Sébastien Lenglet

¹Division of Cardiology, Foundation for Medical Researches, Faculty of Medicine, Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland
Irene Caffa

²First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Debora Soncini

²First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Alessio Nencioni

²First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Jean-Paul Vallée^#

⁴Department of Radiology – CIBM, Geneva, University Hospital, Geneva, Switzerland
François Mach^#

¹Division of Cardiology, Foundation for Medical Researches, Faculty of Medicine, Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland

Abstract

summary

Chemokines trigger leukocyte trafficking and are implicated in cardiovascular disease pathophysiology. Chemokine-binding proteins, called “Evasins” have been shown to inhibit both CC and CXC chemokinemediated bioactivities. Here, we investigated whether treatment with Evasin-3 (CXC chemokine inhibitor) and Evasin-4 (CC chemokine inhibitor) could influence post-infarction myocardial injury and remodelling. C57Bl/6 mice were submitted in vivo to left coronary artery permanent ligature and followed up for different times (up to 21 days). After coronary occlusion, three intraperitoneal injections of 10 μg Evasin-3, 1 μg Evasin-4 or equal volume of vehicle (PBS) were performed at 5 minutes, 24 hours (h) and 48 h after ischaemia onset. Both anti-chemokine treatments were associated with the beneficial reduction in infarct size as compared to controls. This effect was accompanied by a decrease in post-infarction myocardial leukocyte infiltration, reactive oxygen species release, and circulating levels of CXCL1 and CCL2. Treatment with Evasin-4 induced a more potent effect, abrogating the inflammation already at one day after ischaemia onset. At days 1 and 21 after ischaemia onset, both anti-chemokine treatments failed to significantly improve cardiac function, remodelling and scar formation. At 21-day follow-up, mouse survival was exclusively improved by Evasin-4 treatment when compared to control vehicle. In conclusion, we showed that the selective inhibition of CC chemokines (i.e. CCL5) with Evasin-4 reduced cardiac injury/inflammation and improved survival. Despite the inhibition of CXC chemokine bioactivities, Evasin-3 did not affect mouse survival. Therefore, early inhibition of CC chemokines might represent a promising therapeutic approach to reduce the development of post-infarction heart failure in mice.

Keywords

Chemokines - neutrophils - inflammation - acute myocardial infarction

Full Text

References

References
1 Wang YT, Popović ZB, Efimov IR. et al. Longitudinal study of cardiac remodelling in rabbits following infarction. Can J Cardiol 2012; 28: 230-238.
2 Rösner A, Avenarius D, Malm S. et al. Persistent dysfunction of viable myocardium after revascularisation in chronic ischaemic heart disease: implications for dobutamine stress echocardiography with longitudinal systolic strain and strain rate measurements. Eur Heart J Cardiovasc Imaging 2012; 13: 745-755.
3 Montecucco F, Braunersreuther V, Lenglet S. et al. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur Heart J 2012; 33: 1964-1974.
4 Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013; 339: 161-166.
5 Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009; 102: 240-247.
6 Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
7 Montecucco F, Lenglet S, Braunersreuther V. et al. Single administration of the CXC chemokine-binding protein Evasin-3 during ischaemia prevents myocardial reperfusion injury in mice. Arterioscler Thromb Vasc Biol 2010; 30: 1371-1377.
8 Liehn EA, Tuchscheerer N, Kanzler I. et al. Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol 2011; 58: 2415-2423.
9 Déruaz M, Frauenschuh A, Alessandri AL. et al. Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med 2008; 205: 2019-2031.
10 Frauenschuh A, Power CA, Déruaz M. et al. Molecular cloning and characterisation of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus. J Biol Chem 2007; 282: 27250-27258.
11 Vieira AT, Fagundes CT, Alessandri AL. et al. Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. Am J Pathol 2009; 175: 2382-2391.
12 Castor MG, Rezende B, Resende CB. et al. The CCL3/macrophage inflammatory protein-1alpha-binding protein evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice. J Immunol 2010; 184: 2646-2654.
13 Russo RC, Alessandri AL, Garcia CC. et al. Therapeutic effects of evasin-1, a chemokine binding protein, in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 45: 72-80.
14 Copin JC, da Silva RF, Fraga-Silva RA. et al. Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischaemic stroke, but not brain injury in mice. J Cereb Blood Flow Metab 2013; 33: 490-498.
15 Westermann D, Mersmann J, Melchior A. et al. Biglycan is required for adaptive remodelling after myocardial infarction. Circulation 2008; 117: 1269-1276.
16 Montecucco F, Bauer I, Braunersreuther V. et al. Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal 2013; 18: 630-641.
17 Delattre BM, Braunersreuther V, Gardier S. et al. Manganese kinetics demonstrated double contrast in acute but not in chronic infarction in a mouse model of myocardial occlusion reperfusion. NMR Biomed 2012; 25: 489-497.
18 Delattre BM, Van De Ville D, Braunersreuther V. et al. High time-resolved cardiac functional imaging using temporal regularisation for small animal on a clinical 3t scanner. IEEE Trans Biomed Eng 2012; 59: 929-935.
19 Sipola P, Magga J, Husso M. et al. Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation. Eur Radiol 2011; 21: 1383-1389.
20 Lecour S, James RW. When are pro-inflammatory cytokines SAFE in heart failure?. Eur Heart J 2011; 32: 680-685.
21 Liehn EA, Postea O, Curaj A. et al. Repair after myocardial infarction, between fantasy and reality: the role of chemokines. J Am Coll Cardiol 2011; 58: 2357-2362.
22 Kanzler I, Liehn EA, Koenen RR, Weber C. Anti-inflammatory therapeutic approaches to reduce acute atherosclerotic complications. Curr Pharm Biotechnol 2012; 13: 37-45.
23 Braunersreuther V, Pellieux C, Pelli G. et al. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol 2010; 48: 789-798.
24 Liehn EA, Merx MW, Postea O. et al. Ccr1 deficiency reduces inflammatory remodelling and preserves left ventricular function after myocardial infarction. J Cell Mol Med 2008; 12: 496-506.
25 Oral H, Kanzler I, Tuchscheerer N. et al. CXC chemokine KC fails to induce neutrophil infiltration and neoangiogenesis in a mouse model of myocardial infarction. J Mol Cell Cardiol. 2013. Epub ahead of print.
26 Kochs M, Eggeling T, Hombach V. Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death. Eur Heart J 1993; 14 Suppl E 107-119.
27 Elmas E, Lang S, Dempfle CE. et al. High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction. Clin Chem Lab Med 2007; 45: 1360-1365.
28 Misner DL, Frantz C, Guo L. et al. Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys. Br J Pharmacol 2012; 165: 2771-2786.
29 O’Mara E, Kasserra C, Huddlestone JR. et al. Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects. Antimicrob Agents Chemother 2010; 54: 2448-2454.
30 Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 2009; 81: 519-527.